Anita Bellail

Company: HB Therapeutics

Job title: CSO and COO

Seminars:

Discovery & Development of Small-Molecule Glue Degraders of KRAS G12D as the First-in-Class Anticancer Drugs 2:00 pm

Cancer cell-based drug screening identified hit compounds that abide Lipinski rule and degrade active GTP KRAS G12D protein in KRAS G12D mutated cancer cells High-throughput technologies revealed a novel E3 ligase and mechanism of drug action in which degraders bind the E3 ligase and KRAS G12D and induce the KRAS degradation Protein structure-guided and AI-powered…Read more

day: Bootcamp Day